Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure
Anders Götzsche’s shot at R&D glory has ended in defeat at Lundbeck.
The Lundbeck CFO was acting chief when he struck a $1.1 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
